|
KMID : 0378019950380040111
|
|
New Medical Journal
1995 Volume.38 No. 4 p.111 ~ p.116
|
|
|
Clinical Efficacy of Ebastel^(®)(Ebastine) in Patients with Allergic Diseases
|
|
|
|
|
Abstract
|
|
|
Histamine is known to play an active role for allergic disease, so that the main therapeutic indications of the histamine H,-receptor-blocking agents are allergic diseases such as allergic rhinitis, chronic urticaria, bronchial asthma and other conditions in which histamine is a mediator. However the concomitant sedative effects of the classical antihistamines tend to limit their usefulness, and there is a need for new effective and specific antihistamines without such effects.
Ebastine, 4-diphenylmethoxy-l-[3-(4tertbutylbenzoyl) propyl] piperidine, was developed during a search for new antihistamines devoid of the effect on the central nervous system and has been reported to be a potent and selective H,-receptor antagonist with effective clinical efficacy to the allergic diseases.
We conducted this study to assess the clinical efficacy and safety of Ebastel*(Ebastine) in 16 patients with allergic diseases. The patients included in this study were allergic rhinitis(10 cases), chronic urticaria (1 cases), and combined bronchial asthma and allergic rhinitis(5 cases). Ebastel® was given orally 10mg once daily for 1-2 weeks.
The results were follows
1. Significant improvements in clinical symptom scores were noted after administration of Ebastel *(Ebastine) in patients with allergic diseases such as allergic rhinitis, chronic urticaria and bronchial asthma(p<0.05).
2. The clinical efficacy of Ebastel*(Ebastine) was observed in 85.7% of 16 patients with allergic diseases.
3. No specific adverse reactions were observed except mild sedation(I case), mild dry mouth(I case), and mild asthenia(1 case).
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|